Endovascular therapy for superior vena cava syndrome: A systematic review and meta-analysis.
Endovascular therapy for superior vena cava syndrome: A systematic review and meta-analysis.
复制标题
高级腔静脉综合征的血管内治疗：系统评价和荟萃分析。
DOI：
10.1016/j.eclinm.2021.100970
复制
发表时间：
2021-07
影响因子：
15.1
通讯作者：
Bashir R
中科院分区：
文献类型：
--
作者：
Azizi AH;Shafi I;Zhao M;Chatterjee S;Roth SC;Singh M;Lakhter V;Bashir R
上腔静脉（SVC）综合征是由上腔静脉阻塞引起的，可导致显著的发病率和死亡率。在当代实践中，血管内治疗（ET）已成为大多数此类患者的标准治疗方法。本研究是对现有文献的系统回顾和荟萃分析，以评估血管内介入后SVC综合征的技术成功、再狭窄和复发。在这项荟萃分析中，我们对PubMed、Cochrane Library和Embase数据库进行了系统的文献综述，从建立到2021年4月14日，对SVC综合征的ET研究进行了综述。研究包括关于SVC综合征成人使用ET的全文期刊文章。病例报告或病例系列少于20例患者被排除在外。我们评估了SVC综合征患者血管内支架植入术后的技术成功率、再狭窄率和复发率的终点。本研究结果采用随机效应模型计算。我们确定了6012份报告，其中39项研究符合我们的纳入标准并被纳入分析。共有2200例SVC综合征患者接受ET治疗。加权技术成功率为98.8% (95% CI 98.2-99.3)，异质性低（I2=17.4%, p = 0.185），再狭窄率为10.5% (95% CI 8.4-12.6)，异质性中等（I2=53.5%, p<0.001），复发率为10.8% (95% CI 8.1-13.5)，异质性高（I2=75.8%, p<0.001）。总并发症发生率为8.6% (95% CI 7.3% ~ 9.9%)，平均并发症发生率为7.5% （95% CI 4.7% ~ 10.3%）。我们的系统综述显示，ET的技术成功率高，再狭窄率低，复发率低。总的来说，这些结果支持ET作为SVC综合征患者有效和安全的治疗方法。没有。
Superior vena cava (SVC) syndrome is caused by the obstruction of the SVC and can result in significant morbidity and mortality. In contemporary practice, endovascular therapy (ET) has become the standard of care for a majority of these patients. This study is a systematic review and meta-analysis of the available literature to assess technical success, restenosis, and recurrence of SVC syndrome following endovascular intervention. For this meta-analysis, we conducted a systematic literature review of PubMed, Cochrane Library, and Embase databases from inception to April 14, 2021 for studies on ET for SVC syndrome. Studies included full-length journal articles on the use of ET among adults with SVC syndrome. Case reports or case series with fewer than 20 patients were excluded. We evaluated the endpoints of technical success rate, restenosis rate, and recurrence rates in SVC syndrome patients after endovascular stenting. The results of this study were calculated using random-effects models. We identified 6,012 reports, of which 39 studies met our inclusion criteria and were included for analysis. A total of 2200 patients received ET for SVC syndrome. The weighted technical success rate was 98.8% (95% CI 98.2–99.3) with low heterogeneity (I2=17.4%, p = 0.185), restenosis rate was 10.5% (95% CI 8.4–12.6) with moderate heterogeneity (I2=53.5%, p<0.001), and recurrence rate was 10.8% (95% CI 8.1–13.5) with high heterogeneity (I2=75.8%, p<0.001). Total complication rate was 8.6% (95% CI 7.3%-9.9%) with a mean complication rate of 7.5% (95% CI 4.7%-10.3%). Our systematic review revealed high technical success, low restenosis, and low recurrence rates following ET. Collectively, these results support the paradigm of ET as an effective and safe treatment for patients with SVC syndrome. None.
登录
查看更多内容
影响因子：
3.1
作者：
Anton, Susanne;Oechtering, T.;Goltz, J. P.
通讯作者：
Goltz, J. P.
影响因子：
2.9
作者：
Haddad, Mustafa M.;Simmons, Benjamin;Bjarnason, Haraldur
通讯作者：
Bjarnason, Haraldur
影响因子：
--
作者：
Karakhanian, Walter Kegham;Karakhanian, Walter Zavem;Belczak, Sergio Quilici
通讯作者：
Belczak, Sergio Quilici
影响因子：
1.1
作者：
Barshes, Neal R.;Annambhotla, Suman;Lin, Peter H.
通讯作者：
Lin, Peter H.
DOI：
10.1308/rcsann.2020.7127
发表时间：
2021-04-01
影响因子：
1.4
作者：
Irace, L.;Martinelli, O.;Sapienza, P.
通讯作者：
Sapienza, P.